Insurance firm China Life has led a series C round for China-based 3D printing services provider Zhejiang Xunshi Technology sized at tens of millions of dollars, DealStreetAsia reported yesterday.
The corporate took part through China Life Private Equity Investment Company and was joined by Sinopharm Capital, the investment arm of pharmaceutical firm Sinopharm, as well as Qianhai FOF, Kunlun Fund, Keqiao Industry Fund and Chinese Academy of Sciences’ CAS Star unit.
Founded in 2013, Xunshi provides 3D-printed products for customers in industries such as dentistry, healthcare, industrial manufacturing and consumer products.
The capital will fund the launch of the company’s next generation of dental-focused printers and support international growth. It had raised $14.2m in an October 2019 series B round co-led by CD Capital and Marathon Venture Partners.
